20-OCT-2026 6:10

LYMPH ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S2114-NHL, Rel/Ref, CD19 CAR-T +/- Consolidation 1 Y 0 CD19 CAR T-cell Therapy 396 256 90 45 19 6 1 06/12/2023 138 46
            256 90 45 19 6 1      
 
    2 Y 1 Mosunetuzumab   15 6 4 2 1 0 06/12/2023    
        2 Polatuzumab   12 4 1 0 0 0      
        3 Mosunetuzumab + Polatuzumab   14 6 3 1 0 0      
        4 Observation   14 6 3 1 0 0      
            55 22 11 4 1 0      
 
    3 Y 5 Mosunetuzumab + Polatuzumab   4 0 0 0 0 0 06/12/2023    
            4 0 0 0 0 0      
 
  S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa 1 Y 1 Tazemetostat (Arm 1) Dose Level 1 173 7 0 0 0 0 0 09/26/2023 143 40
        10 Tazemetostat (Arm 1) Dose Level 1   6 0 0 0 0 0      
        11 Tazemetostat (Arm 1) Dose Level 2   5 5 0 0 0 0      
        13 Zanubrutinib (Arm 3) Dose Level 2   1 0 0 0 0 0      
        4 Zanubrutinib (Arm 3) Dose Level 1   10 0 0 0 0 0      
        5 Zanubrutinib (Arm 3) Dose Level 2   10 0 0 0 0 0      
        8 Tafasitamab + Lenalidomide   2 2 2 2 2 1      
        9 Tafasitamab + Lenalidomide + Zanubrutinib   2 2 2 2 0 0      
            43 9 4 4 2 1      
 
  S2308-FL, LTB, Mosunetuzumab vs Rituximab 1 Y 1 Rituximab 600 222 126 71 30 12 3 10/23/2024 262 91
        2 Mosunetuzumab   224 128 73 31 11 2      
            446 254 144 61 23 5      
 
  S2506-NHL, R/R MZL, Mozun +/- Zanu or Pola 1 Y 2 Zanubrutinib + Mosunetuzumab 138 1 1 1 1 1 0 10/06/2026 99 28
            1 1 1 1 1 0      
 
Yes A051902-PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P 1 E Total Registrations   19 0 0 0 0 0 10/14/2023 226 80
            19 0 0 0 0 0      
 
  A052101-Lymph, Stg I-IV, Cont v Intermittent Zanub 1 E Total Registrations   38 15 5 3 0 0 01/03/2024 238 78
            38 15 5 3 0 0      
 
    2 E Total Registrations   21 9 7 5 2 0 01/03/2024    
            21 9 7 5 2 0      
 
  AHOD2131-cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy 1 E Total Registrations   115 44 19 5 0 0 08/15/2023 369 133
            115 44 19 5 0 0      
 
    2 E Total Registrations   108 46 23 12 3 0 08/15/2023    
            108 46 23 12 3 0      
 
No A042302-CLL/SLL, Untreated Older, Zan+Son 0 E Total Registrations   12 12 12 7 0 0 06/22/2026 54 18
            12 12 12 7 0 0      
 
    1 E Total Registrations   12 12 12 9 1 0 06/22/2026    
            12 12 12 9 1 0      
 
  EA4231-Lymph, DL B-Cell, Ven+Ib+Pred+Ob+Rev 1 E Total Registrations   1 1 0 0 0 0 03/30/2026 35 9
            1 1 0 0 0 0      
 
  EA4232-Lymph, Peri T Cell, Auto Stem 1 E Total Registrations   2 1 0 0 0 0 09/15/2025 129 38
            2 1 0 0 0 0      
 

20-OCT-2026 6:10

LYMPH Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
A042302 CLL/SLL, Untreated Older, Zan+Son 2 Randomization 06-Mar-26 54 18